Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Rev. bras. hematol. hemoter
; Rev. bras. hematol. hemoter;33(1): 65-72, Feb. 2011. tab
Article
em En
| LILACS
| ID: lil-582750
Biblioteca responsável:
BR408.1
Localização: BR408.1
ABSTRACT
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Prognóstico
/
Pirimidinas
/
Resistência a Medicamentos
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Monitoramento Ambiental
/
Monitoramento de Medicamentos
/
Receptores Proteína Tirosina Quinases
/
Resistencia a Medicamentos Antineoplásicos
/
Mesilato de Imatinib
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Rev. bras. hematol. hemoter
Assunto da revista:
HEMATOLOGIA
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Brasil